Endothelial cell compatibility of clarithromycin for intravenous use Source: Eur Respir J 2006; 28: Suppl. 50, 732s Year: 2006
Effectiveness and safety of gatifloxacin in patients with drug resistance tuberculosus befor unsuccessfully treated with ofloxacin and ciprofloxacin Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
In vitro activity of moxifloxacin and linezolid against mycobacteriaSource: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Intracellular accumulation and bactericidal activity of moxifloxacin and ciprofloxacin in primary respiratory epithelial cells Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis Source: Eur Respir J 2014; 44: 808-811 Year: 2014
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017
Pharmacodynamics of moxifloxacin and four macrolides in the absence or presence of macrophages Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug) Source: Eur Respir J 2001; 18: Suppl. 33, 543s Year: 2001
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Effect of the macrolide azithromycin on Cl secretion by airway epithelial cells in culture Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
Resistance of Streptococcus pneumoniae to penicillin, azitromycin, ciprofloxacyn and ceftriaxon Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016
Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis. Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012